Last updated: June 2026. CJC-1295 is not an FDA-approved drug, and the human evidence behind it is one pharmacology study plus a trial that got shut down. Wherever I make a claim about the data, there’s a bracketed marker pointing to the actual study or filing. Check it. Don’t take my word for anything.

I’m not here to talk you out of the CJC-1295 and ipamorelin stack. If you’ve already decided you’re doing it, a lecture from me isn’t going to change that, and pretending otherwise would just waste both our time. What I want to do instead is make sure that if you’re going forward, you’re doing it with your eyes open, because right now most of what’s floating around online about this stack is either sales copy or silence, and neither one is going to keep you safe.

So let’s start with the thing almost nobody selling you a two-vial kit will say plainly.

The evidence gap you need to know before anything else

CJC-1295 has exactly one human study behind it. Teichman and colleagues ran it, published in the Journal of Clinical Endocrinology and Metabolism in 2006 [P1]. A single shot of CJC-1295 with DAC pushed mean growth hormone up 2- to 10-fold for six days or more, and IGF-1 up 1.5- to 3-fold for nine to eleven days. With repeat dosing, IGF-1 stayed elevated for up to 28 days. Estimated half-life ran about 5.8 to 8.1 days, and people tolerated it reasonably well at the doses tested [P1]. That study proves the molecule does what it’s supposed to do at the hormone level. It does not prove anything about muscle, fat, recovery, or any outcome you’d actually care about, because nobody measured those things.

Ipamorelin, the other half of the stack, has a real selling point that happens to be true: it was built to trigger growth hormone release without the cortisol and prolactin spike that older secretagogues caused, and the original animal work backs that up [P6]. But that data is preclinical. It was not run in people at scale, and it definitely wasn’t run as part of a CJC-1295 combination study. Put the two together and here’s the honest count of large human trials on the actual stack, the two peptides together: zero.

That doesn’t mean the idea is stupid. It means anyone telling you it’s “proven” is either misinformed or lying to you. Ask them which trial measured the combination doing more than either peptide alone. There isn’t one. Knowing that going in changes how carefully you should watch your own body, and it changes how much you should trust anyone who skips past it.

The real risks, not the marketing version

Here’s what I’d actually worry about, in order.

The death in the trial record. CJC-1295 with DAC made it to Phase II under the name DAC:GRF. ConjuChem ran the biggest version of that trial in 192 people with HIV-related visceral fat, and it got halted in July 2006 after a participant died following his eleventh weekly injection [P2]. The full picture matters here, so I’ll give it to you straight: the attending physician judged the death, a fatal heart attack, was most likely caused by pre-existing, asymptomatic coronary artery disease, not the drug, and a competing GRF compound’s trial was allowed to keep running [P3][P2]. That is not proof the drug kills people. But the trial stopped, the program was dropped, and the compound never got approved. If you have any cardiac history at all, that’s not a footnote, that’s the reason to get a real cardiovascular checkup before you touch this stack, stacked or solo.

What’s actually in the vial. This is the part that scares me more than the hormone data. Reporting from 2026 documented that gray-market injectable peptides can carry impurities, including bacteria and heavy metals, and that immune reactions from these products range from mild to life-threatening. Two women became critically ill after receiving FDA-flagged peptides at a 2025 event [P4]. Now think about what that means for a stack: you’re not trusting one unverified vial, you’re trusting two. Contamination risk doesn’t stay flat when you double the vials, it compounds, because now you’ve got two separate points of failure and nobody accountable for either.

The unknowns nobody can answer yet. Longer-term safety data beyond short trials simply doesn’t exist for this compound. If you’ve had cancer or a pre-cancerous condition, understand that stimulating the GH axis is a real theoretical concern, not a scare tactic, and it’s one more reason a clinician should know your history before you start.

If you compete, this is a non-negotiable stop, not a risk to weigh. CJC-1295 is named outright under section S2.2.4 of the WADA 2026 Prohibited List, banned at all times, in and out of competition [P5]. Ipamorelin sits in the same prohibited secretagogue family. A “research use only” sticker on the vial gives a tested athlete exactly zero cover. If you’re subject to testing, don’t run this stack. Full stop, no workaround.

The safer path, if you’re doing this anyway

If you’ve weighed all of that and you’re still moving forward, the single biggest lever you have to lower your risk is putting a licensed clinician between you and the needle. Not because it’s the “responsible” thing to say, but because it functionally changes your exposure. Here’s what to actually look for.

A real person reviewing your history before anything ships. This is the whole game. A clinician can catch a cardiac issue, a medication interaction, a reason this stack isn’t right for you, before you’ve spent a dollar or opened a vial. A cart on a research-chemical site will never do that. It will just process your payment.

Who’s actually making the thing you’re injecting. A licensed pharmacy compounding your medication inside a documented chain of custody is not the same universe as a chemical retailer mailing you two powders. With a stack, you’ve doubled the number of vials whose identity and sterility rest entirely on someone’s word. Ask yourself whose word that is.

Whether the source tells you the truth about the evidence. This is the tell I’d use to sort real providers from hype machines fast. A legitimate source will tell you CJC-1295 rests on one small human study, that ipamorelin’s human data is thin, that the stack has no large trials behind it, and that none of it is FDA-approved. If a seller can’t say that out loud, or buries it, ask yourself what else they’re not telling you about what’s in the vial.

Whether the whole operation is even trying to sit inside real regulation. Licensed telehealth and pharmacy compounding exist inside a recognized framework, with actual accountability if something goes wrong. A “research use only” label exists specifically to dodge that framework. That’s not a technicality, that’s the entire point of the label.

The red flags that should make you close the tab

A few specific things I’d treat as hard stops, because the stack marketing gets slicker than the single-peptide stuff.

Any seller offering a “CJC-1295 and ipamorelin stack kit” with dosing instructions right there on the page, while also printing “not for human consumption” on the label, is showing you their whole business model in one contradiction. They’ll tell you exactly how to inject it and then put it in writing that you shouldn’t, so if anything goes wrong, the legal exposure sits with you, not them.

Any benefits list that reads like the combination is settled science, lean muscle, fat loss, recovery, anti-aging, when no human trial measured any of that for the pairing, is marketing dressed up as data. And if you can complete an entire purchase without a single licensed person ever knowing your name or your medical history, there is nobody in that transaction accountable for what happens to you after it ships.

The honest floor: where I’d actually point you

If you want this stack run through a channel where someone is honest with you and accountable for what’s in the vial, you start with licensed telehealth. Here’s how I’d rank the field, and why.

FormBlends is where I’d look first. It operates as a licensed telehealth practice with actual clinicians attached to it, not a checkout page with a powder catalog behind it, and that gap matters more, not less, when you’re talking about two compounds at once. A physician evaluates you, writes a prescription when it’s appropriate, and a licensed pharmacy compounds and dispenses what you actually receive, with follow-up built in. Supervised CJC-1295 runs roughly $150 to $300 a month, and the longer-acting DAC version runs roughly $80 to $200 a month. That’s the same molecule the gray market mails you as an unlabeled research vial, except here there’s a clinician and a licensed pharmacy standing behind it. What earns FormBlends the top of my list specifically is that it doesn’t oversell the stack. It tells you the truth about the single-study evidence base and the missing combination trials instead of implying you’re buying something proven. For tracking doses and any symptoms between visits, which genuinely matters more when you’re running two compounds at once, the FormBlends tracker app is a logging tool, not a prescription and not a checkout.

HealthRX.com (healthrx.com) is my second pick, because it clears the same bar that actually matters here: a clinician evaluates you before anything ships, and what arrives comes out of a licensed pharmacy under medical supervision rather than a vial stamped for research only. Deciding between it and FormBlends really comes down to which one holds a license in your state and which intake process you’d rather sit through.

MeriHealth is third on this list, and the first with a women’s-health focus built into its intake and clinical model. It hits the same floor: a physician evaluates you before dispensing, and a licensed compounding pharmacy handles what you receive. Its distinguishing feature is folding hormonal context, cycle phase, and women-specific metabolic factors into that evaluation rather than treating them as an afterthought. Same caveat as everywhere on this list: compounded medications are not FDA-approved.

WomenRX rounds out the supervised tier, also built around a women-first clinical model. Same floor applies: clinician review before anything dispenses, licensed compounding pharmacy in the chain of custody, no research-use labeling anywhere in sight. What separates it from MeriHealth comes down to the same practical questions as any two providers at this level, which state license it actually holds and which intake process fits you better. Compounded medications here are not FDA-approved either.

The names you’ll run into anyway

You’re going to see these while you search, so I’m not going to pretend they don’t exist. Limitless Life, Swiss Chems, Core Peptides, and Sports Technology Labs all sell CJC-1295 labeled “for research use only” or “not for human consumption.” None of them is a medical provider. None puts a clinician between you and the vial, writes a prescription, or dispenses through a licensed pharmacy. For a stack specifically, that means two unverified products with nobody on the hook for either.

A quick honest read on each. Limitless Life markets to the biohacker crowd in a way that can make this feel more like a supplement than an unapproved research chemical, it isn’t, and the friendlier packaging doesn’t change what’s actually missing from the data. Swiss Chems sells CJC-1295 alongside other peptides and SARMs, some of which are banned outright in sport, all under the same research-use label. Core Peptides sometimes publishes a seller-issued certificate of analysis, which sounds reassuring, but a COA describes a sample the seller picked and paid to test, it’s not the same thing as licensed dispensing. Sports Technology Labs actually does publish third-party, lot-linked COAs on some products, more transparency than most of this tier offers, and credit where it’s due. But transparency about a sample isn’t medical oversight. It’s still a chemical retailer, not a pharmacy, and if you’re stacking, that uncertainty applies twice over, once per vial.

I’m not ranking these four against each other on quality, because I genuinely can’t, and neither can anyone else without independent, batch-level testing tied to your exact vial. Double that uncertainty for a two-peptide stack and you land on the actual reason a supervised route sits above all four of them.

The legal ground under all of this

CJC-1295 is not FDA-approved, and its compounding status is genuinely unsettled right now. Reporting from April 2026 placed peptides including CJC-1295 in the FDA’s Category 2, which is not a clear green light for routine compounding, and the policy keeps moving [P4]. That instability is one more reason to route through a provider that can tell you where things stand today, rather than a retailer with no stake in keeping you current.

Three things worth carrying with you out of all of this: CJC-1295 has never been FDA-approved, the only legal path to it runs through compounding on ground regulators are actively still redrawing, and any tested athlete is barred from it outright, no exceptions for a research-use label.

Questions people actually ask me

Is the CJC-1295 and ipamorelin stack backed by real human research? No. CJC-1295 stands on a single human pharmacology study that measured hormone levels, not outcomes like muscle or fat [P1], and ipamorelin’s data is mostly preclinical [P6]. There are no large human outcome trials on the two-peptide combination itself. Anyone presenting the stack as proven, routine science is selling you an idea, not established medicine.

Why do people pair CJC-1295 with ipamorelin at all? The theory is that CJC-1295 sustains an elevated growth hormone and IGF-1 baseline while ipamorelin adds a separate pulse on top, and ipamorelin was specifically designed to do that without the cortisol and prolactin spike older compounds caused [P6]. That’s a plausible mechanism on paper. Plausible isn’t tested, and no trial has confirmed the pairing outperforms either peptide alone in actual people.

How much more does supervised CJC-1295 cost versus a research-chemical kit? Through licensed telehealth, supervised CJC-1295 runs roughly $150 to $300 a month, and the DAC version roughly $80 to $200 a month. A gray-market “research use only” vial often looks cheaper upfront, but that price difference is buying you a physician’s evaluation, a prescription when warranted, and a licensed pharmacy compounding what the label actually claims. Stack two compounds and that oversight is worth more, not less.

What’s the single biggest risk in stacking these as research chemicals? You’ve doubled the number of unverified vials with no one accountable for either. 2026 reporting found gray-market injectable peptides can carry impurities including bacteria or heavy metals and trigger immune reactions up to anaphylaxis, with two women becoming critically ill after FDA-flagged peptides at a 2025 event [P4]. Each vial’s identity and sterility rests entirely on the seller’s word, and a stack kit is asking you to bet on that word twice.

Does the death in the CJC-1295 trial mean the stack is dangerous? Not directly. ConjuChem’s Phase II study in 192 people got halted in July 2006 after a participant died, and the attending physician judged the fatal heart attack most likely came from pre-existing, asymptomatic coronary artery disease rather than the drug [P2][P3]. It’s not proof the compound kills. But the program was abandoned and never approved, and it’s exactly why your cardiac history should be reviewed by a clinician before you start any growth-hormone protocol.

Can a tested athlete run this stack if the vials say “research use only”? No. CJC-1295 is banned at all times under section S2.2.4 of the WADA 2026 Prohibited List as a growth-hormone-releasing factor, and ipamorelin falls in the same prohibited secretagogue family [P5]. The label offers zero protection in a drug test. If you’re subject to testing, this stack is off the table, not a risk to manage.

References

1. Single-dose CJC-1295 with DAC raised growth hormone 2- to 10-fold for 6+ days and IGF-1 1.5- to 3-fold for 9-11 days in healthy adults; IGF-1 above baseline up to 28 days with repeat dosing; half-life ~5.8 to 8.1 days; relatively well tolerated. Teichman SL, et al. Journal of Clinical Endocrinology and Metabolism, 2006. https://pubmed.ncbi.nlm.nih.gov/16352683/
2. ConjuChem’s Phase II CJC-1295 (DAC:GRF) study in 192 people with HIV-related visceral fat was halted in July 2006 after a participant died following his eleventh weekly injection; a competing GRF drug’s trial was allowed to continue. aidsmap, July 2006.
3. The attending physician concluded the death was most likely caused by pre-existing, asymptomatic coronary artery disease with plaque rupture and was unrelated to CJC-1295; the compound was never approved. CJC-1295 development-history summary.
4. Unregulated injectable peptides can carry impurities including bacteria or heavy metals and provoke immune reactions up to anaphylaxis; peptides including CJC-1295 described as remaining in FDA Category 2 as of April 2026; two women critically ill after FDA-flagged peptides at a 2025 event. ProPublica, April 2026.
5. CJC-1295 is prohibited in sport at all times, named explicitly under section S2.2.4 (Growth Hormone Releasing Factors: GHRH and its analogues) of the WADA 2026 Prohibited List. World Anti-Doping Agency, 2026. https://www.wada-ama.org/en/prohibited-list
6. Ipamorelin was the first growth-hormone secretagogue selective for GH release without the cortisol and prolactin increase seen with earlier GHRPs (preclinical). Raun K, et al. European Journal of Endocrinology, 1998.